← Back

Medrx Co., Ltd.

MedRx Co., Ltd. is a pharmaceutical formulation development company based in Higashikagawa, Japan, incorporated in 2002. It develops transdermal medicines using its ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS), as well as microneedle arrays and patch vaccines for delivering vaccines and APIs through the skin. Its pipeline includes MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT in Phase II for spastic paralysis; Alto-101 in Phase II for schizophrenia; MRX-9FLT in Phase I for moderate to severe pain; and MRX-6LDT in formulation development for chronic pain.

Country
Price · split & dividend adjusted
News & notes moving 4586.JP
4586.JP

Kuklev Partners with L-Line, Medrek Signs US Distribution Deal for Bondlido

Kuklev has formed a business partnership with L-Line, which handles scaffolding, earthwork, and structural framework construction. The company also raised its year-end dividend from 27.00 yen to 30.00 yen per share. Medrek has entered into a distribution agreement and a launch contract with Terrain for Bondlido in the United States.
フィスコ·67dRead more →